ES2038712T3 - Un procedimiento para preparar un compuesto util como inhibidor de esteroide c17-20 liasa. - Google Patents

Un procedimiento para preparar un compuesto util como inhibidor de esteroide c17-20 liasa.

Info

Publication number
ES2038712T3
ES2038712T3 ES198888106397T ES88106397T ES2038712T3 ES 2038712 T3 ES2038712 T3 ES 2038712T3 ES 198888106397 T ES198888106397 T ES 198888106397T ES 88106397 T ES88106397 T ES 88106397T ES 2038712 T3 ES2038712 T3 ES 2038712T3
Authority
ES
Spain
Prior art keywords
liasa
preparing
procedure
compound useful
steroid inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888106397T
Other languages
English (en)
Inventor
Michael R. Angelastro
Thomas R. Blohm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2038712T3 publication Critical patent/ES2038712T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A DICHO COMPUESTO Y A COMPUESTOS ANALOGOS Y TAMBIEN A UN METODO PARA EMPLEAR DICHOS COMPUESTOS EN EL TRATAMIENTO DE ALTERACIONES DEPENDIENTES DE ANDROGENOS. LOS COMPUESTOS SE PREPARAN POR REDUCCION DE ANDROGENOS. LOS COMPUESTOS SE PREPARAN POR REDUCCION CON HIDRUROS DE UNA IMINA O ENAMINA ESTEROIDICA APROPIADA.
ES198888106397T 1987-04-22 1988-04-21 Un procedimiento para preparar un compuesto util como inhibidor de esteroide c17-20 liasa. Expired - Lifetime ES2038712T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22

Publications (1)

Publication Number Publication Date
ES2038712T3 true ES2038712T3 (es) 1993-08-01

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888106397T Expired - Lifetime ES2038712T3 (es) 1987-04-22 1988-04-21 Un procedimiento para preparar un compuesto util como inhibidor de esteroide c17-20 liasa.

Country Status (19)

Country Link
EP (1) EP0288053B1 (es)
JP (1) JP2711672B2 (es)
KR (1) KR960015037B1 (es)
CN (1) CN88102176A (es)
AT (1) ATE67211T1 (es)
AU (1) AU606677B2 (es)
CA (1) CA1326234C (es)
DE (1) DE3864725D1 (es)
DK (1) DK217588A (es)
ES (1) ES2038712T3 (es)
FI (1) FI88397C (es)
GR (1) GR3002713T3 (es)
HU (1) HU198511B (es)
IL (1) IL86139A (es)
NO (1) NO169346C (es)
NZ (1) NZ224288A (es)
PH (1) PH24090A (es)
PT (1) PT87294B (es)
ZA (1) ZA882717B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
JP2742331B2 (ja) * 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
ATE327237T1 (de) 2000-11-17 2006-06-15 Takeda Pharmaceutical Imidazol derivate, ihre herstellung und ihre verwendung
EP1344777B1 (en) 2000-11-20 2011-03-16 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
CA2765983C (en) 2009-06-26 2017-11-14 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
CA3044812A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (es) * 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
CN88102176A (zh) 1988-11-23
DK217588D0 (da) 1988-04-21
AU606677B2 (en) 1991-02-14
HU198511B (en) 1989-10-30
IL86139A (en) 1993-02-21
PH24090A (en) 1990-03-05
FI88397C (fi) 1993-05-10
NZ224288A (en) 1989-12-21
EP0288053B1 (en) 1991-09-11
HUT47307A (en) 1989-02-28
ZA882717B (en) 1988-10-17
NO881746D0 (no) 1988-04-21
NO169346B (no) 1992-03-02
FI88397B (fi) 1993-01-29
AU1471988A (en) 1988-10-27
PT87294A (pt) 1988-05-01
NO169346C (no) 1992-06-10
FI881877A0 (fi) 1988-04-21
NO881746L (no) 1988-10-24
CA1326234C (en) 1994-01-18
IL86139A0 (en) 1988-11-15
KR880012633A (ko) 1988-11-28
JPS63284195A (ja) 1988-11-21
EP0288053A1 (en) 1988-10-26
ATE67211T1 (de) 1991-09-15
PT87294B (pt) 1992-08-31
KR960015037B1 (ko) 1996-10-24
JP2711672B2 (ja) 1998-02-10
GR3002713T3 (en) 1993-01-25
DE3864725D1 (de) 1991-10-17
FI881877A (fi) 1988-10-23
DK217588A (da) 1988-10-23

Similar Documents

Publication Publication Date Title
ES2038712T3 (es) Un procedimiento para preparar un compuesto util como inhibidor de esteroide c17-20 liasa.
ZA906308B (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20lyase inhibitors
LTIP919A (en) Drugs and process for preparing thereof
PH27549A (en) 4-Substituted 17b- cyclo-propyloxy)androst-5-en-3beta- ol and related compounds useful as c17-20 lyase inhibitors
ES2133582T3 (es) Esteroides heterociclicos de c17 delta16-insaturados utiles como inhibidores de esteroide c17-20 liasa.
IL86140A (en) 17-(cyclopropyloxy) androst-5-en-3-ol and pharmaceutical compositions useful as c17-20 lyase inhibitors
ZA939807B (en) Derivatives of benzoylecgonine ecgonine and ecgonidine and methods for preparing and using same
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
DE69810340D1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
ATE137758T1 (de) Verfahren zur herstellung von nojirimycin- verbindungen
ATE61804T1 (de) Verfahren zur aminolyse von sterolestern.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 288053

Country of ref document: ES